CYP19A1 and neoplasm: Having observed fluctuations in cell numbers in patients with an irregular Tamoxifen intake, we found that in patients with increasing cell numbers after stopping endocrine treatment re-intake of Tamoxifen or switch to aromatase inhibitors again reduced the number of circulating tumor cells and no patient suffered from relapse in the observation period.